Actively Recruiting
Development and Clinical Translation of immunoPET Imaging Probes for Digestive System Carcinoma
Led by RenJi Hospital · Updated on 2025-12-31
400
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating target-specific immunoPET/CT imaging methods for digestive system carcinomas, including various malignant tumors in the digestive tract. This study aims to establish optimal imaging techniques and understand the physiological and pathological distribution of these imaging agents. The diagnostic effectiveness of these agents will be assessed, focusing on their ability to detect malignant tumors in the digestive system. Participants will receive one of several target-specific radioactive probes designed to highlight cancer cells during PET/CT scans. These probes include HER2-targeted, Trop2-targeted, GPC3-targeted, GPA33-targeted, and Nectin-4-targeted agents, each given at a dose of 0.05-0.1 mCi/kg. Whole-body PET/CT scans will be performed 1 to 2 hours after injection to visualize tumor uptake, which will be scored both visually and quantitatively. During the study, researchers will measure the distribution of the tracers in the body, including maximum standardized uptake values (SUVmax) in tumors. They will evaluate diagnostic accuracy by calculating sensitivity, specificity, and predictive values, and correlate tracer uptake with protein expression in tumor tissue. Secondary outcomes include the tracers' predictive value for immunotherapies and targeted therapies over 3 to 6 months. Participants will be monitored for radiation dosimetry and safety, with study participation lasting up to several months depending on outcomes assessed.
CONDITIONS
Brief Title
Target-specific immunoPET Imaging of Digestive System Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18-75 years old and of either sex
- Histologically confirmed diagnosis of digestive system carcinoma or suspected digestive system carcinoma by diagnostic imaging
- Able to give signed informed consent and comply with study requirements
You will not qualify if you...
- Pregnant
- Severe liver or kidney failure
- History of serious surgery in the last month
- Allergy to antibody or single-domain antibody radiopharmaceuticals
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants receive a targeted-specific immunoPET/CT scan 1 to 2 hours after injection of a radioactive tracer targeting specific proteins related to digestive system carcinoma.
1 imaging visit (in-person)
Duration - Up to 6 months
Participants are monitored to evaluate diagnostic value, correlation between tracer uptake and target expression, and predictive value in therapy response over several months.
Follow-up visits over 3 to 6 months
Trial Site Locations
Total: 1 location
1
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China, 200127
Actively Recruiting
Research Team
W
Weijun Wei, Ph.D. & M.D.
S
Shuxian An, Ph.D. & M.D.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here